Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and bu

Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for pa

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropat

Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raise

Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings larg

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy a

B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and rais

BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price ta

Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being de

Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the pri

Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial as

Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA n

~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA

WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinica

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy a

Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises

Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consen

Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their

Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)'s stock price reached a new 52-week high during tra

Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the pr

Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy

 Up to $100,000,000Common StockWe have entered into an Open Market Sale AgreementSM, or the Sales Ag

Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of it

Climb Bio (CLYM) shares positive Phase 1b data for budoprutug in ITP, showing robust B-cell depletio

BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price ta

Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for pa

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging

U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive tr

Guggenheim analyst Yatin Suneja initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating a

The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotl

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight

WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical

Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during

WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical

WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, sup

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, sup

WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinica

Climb Bio, Inc. maintains a Buy rating, driven by budoprutug's strong phase 1b and long-term data in

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S